GnRH Analogues in the Prevention of Ovarian Hyperstimulation Syndrome

Alamá, Pilar; Bellver, José; Vidal, C.; Gilés, Juan

doi:10.5812/ijem.5034

Cited by 11 publications

(11 citation statements)

References 98 publications

(111 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Different studies on human and animal models have shown that in OHSS, some mediatory compounds are released from the ovaries that increase capillary permeability and liquid assembly in the peritoneal cavity [2,22,23]. Although the pathophysiology of this syndrome is not completely revealed, it seems that the release of vasoactive and angiogenic substances lead to leakage, hyperpermeability of liquid and shift of fluids from blood vessels into the extravascular space and have a role in this syndrome [24][25][26].…”

Section: Discussionmentioning

confidence: 99%

“…One of the most important signs of this syndrome is the enlargement of ovaries in which luteal and hemorrhagic cysts along with a shift of liquids into the peritoneal cavity. Polishuk et al reported that the release of various compounds from the ovaries leads to an increase in capillary permeability and, hence, liquid shift from the intravascular compartment into the peritoneal cavity [2,27].…”

Section: Discussionmentioning

confidence: 99%

“…Infertility, as a condition prevailing worldwide, affects 11-15% of reproductive-age couples. Novel methods have been partially able to regulate this problem, but these methods also have various negative effects [1][2][3][4]. The Ovarian Hyperstimulation Syndrome (OHSS), the most severe complication of ovulation stimulation occurring after gonadotropin application, is one of the mentioned effects [5,6].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Ovarian hyperstimulation syndrome model in mice: effect of GnRH agonist

Moradi¹,

Hosseini²,

Mohammadi‐Yeganeh³

et al. 2018

biomedicalresearch

View full text Add to dashboard Cite

Introduction: Ovarian Hyperstimulation Syndrome (OHSS) is one of the most severe complications caused by ovarian stimulation during which the ovaries become severely stimulated and endanger an individual's health. Since the negative effects of OHSS are not really clear, an animal model was needed in order to evaluate OHSS effects on the embryo. Previous studies failed to produce any OHSS model in mouse with a large amount of oocyte. The present study aimed to evaluate the role of GnRH agonist on the number and maturation of oocytes and the preimplantation development of embryo in a mouse model of OHSS. Method: Mice were divided into 4 groups-superovulation, OHSS with GnRH agonist and OHSS without GnRH agonist, and control. The OHSS with GnRH agonist and OHSS without GnRH agonist groups were created using the defined protocol, and, in the following stages, the oocytes were collected after euthanizing the mice and prepared for in vitro fertilization (IVF), and after performing IVF, the preimplantation development of embryos was evaluated. Results: The results showed that, in the OHSS mouse model, the rate of oocyte maturation significantly improved in the treated GnRH agonist group comparing to the untreated GnRH agonist group. Fertilization and preimplantation development were significantly lower in the untreated GnRH agonist OHSS group. Conclusion: With regard to the positive effects of GnRH agonist on oocyte number, oocyte maturation and preimplantation stages of embryos of mouse model, it seems that GnRH agonist can be used in order to improve the results of fertilization in the mouse model of OHSS.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ovarian hyperstimulation syndrome model in mice: effect of GnRH agonist

Moradi¹,

Hosseini²,

Mohammadi‐Yeganeh³

et al. 2018

biomedicalresearch

View full text Add to dashboard Cite

show abstract

“…GnRH agonistinin reseptör düze-yinde antagonistin yerine geçmesiyle reseptör aktive olacak ve gonadotropin salınımı olacaktır (flare etki). 49 …”

Section: Gnrh Agoni̇st Vs Antagoni̇st Protokollerunclassified

Controlled Ovarian Stimulation in IVF Cycles

Gürgan¹,

Gülerman²,

Özyer³

2017

TJRMS

View full text Add to dashboard Cite

42n vitro fertilizasyon (IVF) sonrası ilk başarılı doğum, spontan ovulatuar siklusta tek bir oosit elde edilip tek embryo transferi yapılmasıyla sağlanmıştır. Ancak bu yöntemin başarı oranı dü-şüktür ve günümüzde klinisyenler çok sayıda follikülün senkron gelişimini sağlayacak ovaryan stimülasyon stratejilerinin kullanımını benimsemişlerdir. Kontrollü ovaryan stimülasyon (KOS), IVF tedavisi dahilinde overlerden en ideal sayı ve kalitede oosit elde etmek amacı ile aynı siklusta çok sayıda follikülün geliştirilmesidir. 1970'li yıllardaki ilk uygulamalardan itibaren KOS, IVF'in temel basamaklarından birini oluşturmaktadır. Oosit kalitesini ve canlı doğum oranlarını artırmak, düşük over rezervi olan hastalarda over yanıtını iyileştir-mek ve ovaryan hiperstimülasyon riskini azaltmak amacıyla çeşitli KOS protokolleri geliştirilmiştir. A An na ah h t ta ar r K Ke e l li i m me e l le er r: : İn vitro fertilizasyon; kontrollü ovaryan stimülasyon; protokol A AB BS S T TR RA AC CT T After the first live birth through a natural cycle in vitro fertilization (IVF) trial in 1978, advances in assisted reproductive techniques (ART) have been rapidly proceeded. Since then, more than 5 million pregnancies have been achieved worldwide by IVF and other modified techniques generally named as ART. As the experience and the success rates have increased, the indications for ART also expands. With the advances in reproductive biology, laboratory and pharmaceutical sciences, there is increasing attention on the importance of controlled ovarian stimulation (COS) to the IVF outcomes. Individualized COS (iCOS ) practices will improve IVF outcomes and safety issues. The aim of this review is to go through the fundamentals of COS and its best practices in ART.

show abstract

“…Research published on the issue reveals that the frequency of ovarian hyperstimulation syndrome varies from 0.5% to 33% with different schemes of ovulation stimulation and does not reveal a downward trend. Severe forms of the syndrome that require hospitalization have been diagnosed in 0.2-10% of all cases [15].…”

Section: Introductionmentioning

confidence: 99%

Epidemiology of critical states during pregnancy after assisted reproductive technologies

Bashmakova¹,

Davydenko²,

Malgina³

et al. 2016

Gynecological Endocrinology

View full text Add to dashboard Cite

Aim: The aim of this research was to have a thorough study of predictors of critical states during pregnancy after assisted reproductive technologies. Materials and methods: A retrospective study of 303 patients with ''near-miss,'' out of which 37 are pregnancy cases after ART (the main group) and 265 are spontaneous pregnancy cases (the control group). Results: Pregnancy after ART constituted 12.3% of all critical states. In the main group (10.8%), severe ovarian hyperstimulation prevailed over all possible reasons for critical states within the period of up to 22 weeks of gestation, whereas bleeding predominated in the control group (57.1%). When pregnancy terms exceeded 22 weeks, the leading reason for ''near-miss'' in the main group was preeclampsia (59.5%) with underlying thrombophilia (29.7%) and gestation pancreatic diabetes (32.4%); bleeding was the main factor in the control group (36.6%). Conclusion: Women after assisted reproductive technologies constitute a high-risk group for critical obstetric states not only in the nearest time period but also long after ART.

show abstract

GnRH Analogues in the Prevention of Ovarian Hyperstimulation Syndrome

Cited by 11 publications

References 98 publications

Ovarian hyperstimulation syndrome model in mice: effect of GnRH agonist

Ovarian hyperstimulation syndrome model in mice: effect of GnRH agonist

Controlled Ovarian Stimulation in IVF Cycles

Epidemiology of critical states during pregnancy after assisted reproductive technologies

Contact Info

Product

Resources

About